[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100603128":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":24,"centralContacts":28,"locations":10,"responsibleParty":36,"collaborators":10,"id":39,"slug":40,"hasResults":41,"nctId":42,"briefTitle":43,"officialTitle":44,"acronym":45,"eligibilityCriteria":46,"healthyVolunteers":41,"sex":47,"minAge":10,"maxAge":10,"enrollmentInfo":48,"targetDuration":51,"studyType":52,"phases":10,"briefSummary":53,"conditions":54,"keywords":10,"overallStatus":57,"whyStopped":10,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":10},{"fullName":5,"class":6},"Assiut University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"No-Reflow Group",null,"STEMI patients undergoing primary PCI who develop angiographic no-reflow, defined as final TIMI flow ≤2 and\u002For Myocardial Blush Grade (MBG) 0-1 after stent deployment in the absence of mechanical obstruction (no dissection, spasm, residual thrombus, or significant residual stenosis). Planned enrollment: 56.",[13],"Diagnostic Test: HbA1c\u002FC-peptide ratio Albumin-bilirubin (ALBI) score. Neutrophil\u002FHDL ratio",{"label":15,"type":10,"description":16,"interventionNames":17},"Reflow Group","STEMI patients undergoing primary PCI who achieve successful epicardial and microvascular reperfusion, defined as final TIMI 3 flow and MBG 2-3 after PCI. Planned enrollment: 56.",[13],[19],{"type":20,"name":21,"description":22,"armGroupLabels":23,"otherNames":10},"DIAGNOSTIC_TEST","HbA1c\u002FC-peptide ratio Albumin-bilirubin (ALBI) score. Neutrophil\u002FHDL ratio","1. To investigate whether the HbA1c to C-peptide ratio can serve as a predictive marker for no-reflow, reflecting the impact of chronic glycemic control and pancreatic beta-cell function.\n2. To evaluate the neutrophil-to-HDL ratio as a potential indicator of no-reflow, representing the balance between systemic inflammation and endogenous vascular protection.\n3. To examine the prognostic value of the albumin-bilirubin (ALBI) score in identifying patients at higher risk for no-reflow, considering the systemic influence of hepatic function and inflammation.",[9,15],[25],{"name":26,"affiliation":10,"role":27},"Hossam H. Ali","PRINCIPAL_INVESTIGATOR",[29,34],{"name":30,"role":31,"phone":32,"phoneExt":10,"email":33},"Hossam E. A. Abdelhafiz","CONTACT","00201143999651","Hossamalaa203040@gmail.com",{"name":35,"role":31,"phone":10,"phoneExt":10,"email":10},"Marwan S. Mahmoud",{"type":27,"investigatorFullName":37,"investigatorTitle":38,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"Hossam Eldin Alaa Abdelhafiz mohamed","Principal investigator, cardiology Department","100603128","validation-of-new-biomarkers-for-predicting-no-reflow-in-stemi-patients-undergoing-primary-pci-100603128",false,"NCT07132489","Validation of New Biomarkers for Predicting No-Reflow in STEMI Patients Undergoing Primary PCI","Validation of Novel Metabolic, Inflammatory, and Hepatic-Renal Biomarkers-HbA1c\u002FC-peptide Ratio, Neutrophil\u002FHDL Ratio, and ALBI Score-for Predicting the No-Reflow Phenomenon After Primary PCI in Patients With STEMI.","VaBiNoR","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Suitable for and undergoing timely primary PCI based on symptoms and clinical judgment\n* Provision of informed consent\n\nExclusion Criteria:\n\n* History of previous MI, PCI, or CABG\n* Known chronic inflammatory or autoimmune diseases\n* Advanced renal or hepatic failure\n* Active infection or malignancy at presentation\n* Incomplete data or refusal to consent","ALL",{"count":49,"type":50},114,"ESTIMATED","1 Month","OBSERVATIONAL","To evaluate the diagnostic value of the selected emerging biomarkers in predicting the no-reflow phenomenon among patients presenting with STEMI undergoing primary PCI. These biomarkers include:\n\nHbA1c\u002FC-peptide ratio\n\nAlbumin-bilirubin (ALBI) score.\n\nNeutrophil\u002FHDL ratio",[55,56],"Myocardial Infarction","No Reflow Phenomenon","NOT_YET_RECRUITING","2025-08-25",{"date":60,"type":61},"2025-08-29","ACTUAL",{"date":63,"type":50},"2025-09-01",{"date":65,"type":50},"2028-12-01",{"name":5,"class":6}]